NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed a deal under which its full suite of microRNA testing services and molecular diagnostics will be covered by the more than 1,700 payors belonging to America's Choice Provider Network (ACPN).

The arrangement, which also includes offerings from Rosetta's recently acquired PersonalizeDx subsidiary, will make the company's tests and services available to more than 22 million ACPN members. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.